Synthroid vs Cytomel (Liothyronine): Which Thyroid Medication Works Better for Women?

What Is the Core Difference Between Levothyroxine and Liothyronine?

Levothyroxine is a synthetic form of thyroxine (T4), the main hormone produced by your thyroid gland. Your body converts T4 into triiodothyronine (T3), the biologically active form that enters cells and drives metabolism. Liothyronine is synthetic T3, so it acts directly without that conversion step.

In practice, this means levothyroxine works gradually, with a half-life of roughly seven days, producing stable, predictable blood levels. Liothyronine peaks in one to two hours and clears within about 24 hours, which can cause noticeable swings in energy, heart rate, and mood if not dosed carefully.

The 2014 American Thyroid Association guidelines recommend levothyroxine monotherapy as the standard treatment for hypothyroidism for most patients. That recommendation has not changed as of the most recent ATA updates.

Why T4-to-T3 Conversion Matters More for Women

Women are five to eight times more likely than men to develop hypothyroidism, and the way female hormones interact with thyroid physiology is not trivial. Estrogen raises levels of thyroxine-binding globulin (TBG), the protein that carries T4 in your blood. Higher TBG means more T4 is bound and unavailable, so your free T4 drops, and your dose requirements rise. This effect is pronounced during pregnancy and when taking oral estrogen (including combined oral contraceptives).

Progesterone has a competing effect, slightly lowering TBG, which is why thyroid needs can fluctuate across your menstrual cycle in women with borderline thyroid function. Some women with Hashimoto's thyroiditis report symptom flares in the luteal phase for this reason, though large controlled data on this are limited (see W6 note below).

The Conversion Problem: Not All Women Convert T4 to T3 Equally

Peripheral conversion of T4 to active T3 is controlled largely by deiodinase enzymes, particularly type-2 deiodinase (DIO2). A common DIO2 polymorphism (Thr92Ala) has been associated with reduced intracellular T3 production. One analysis found that women carrying this variant reported worse well-being on T4 monotherapy and preferred T4/T3 combination. The variant is present in roughly 12-36% of the general population. This is not yet standard clinical testing, but it explains why some women feel persistently symptomatic despite a normal TSH on levothyroxine alone.

What Does the Head-to-Head Evidence Actually Show?

There is no single large randomized controlled trial comparing levothyroxine monotherapy to liothyronine monotherapy in hypothyroid women with quality-of-life as the primary outcome. Most of the head-to-head data compares levothyroxine alone to levothyroxine-plus-liothyronine combination, not T3 alone as a replacement.

The Bunevicius 1999 NEJM Trial

The most cited piece of evidence in this debate is Bunevicius et al., published in the New England Journal of Medicine in 1999. In a crossover trial of 33 patients with hypothyroidism (the majority women, though the paper does not sex-stratify outcomes), substituting 12.5 mcg of liothyronine for 50 mcg of levothyroxine daily improved scores on 17 of 19 measures of mood, cognition, and physical well-being compared to T4 alone. Serum T3 rose and serum T4 fell, while TSH remained similar between arms.

This was a small, short-duration trial, and its results have not been consistently replicated. A 2003 NEJM trial by Appelhof et al. found no overall benefit from adding T3 to T4, though a subgroup analysis suggested women with lower body weight and more severe symptoms at baseline may have fared better.

What Larger Reviews Conclude

A Cochrane systematic review published in 2013 and updated subsequently analyzed data from 11 randomized trials comparing T4 monotherapy to T4/T3 combination therapy. The review found no consistent benefit of combination therapy over T4 alone for quality of life, mood, or cognitive function in the overall population. However, the authors noted that roughly 50% of participants in some trials expressed a preference for the combination, suggesting a real and clinically meaningful subgroup exists whose needs are not met by T4 alone.

The evidence gap here is not subtle. Most trials are small, use different T3 doses and ratios, and rarely report results separated by sex. Women, who make up the overwhelming majority of hypothyroid patients, have paradoxically been studied as an afterthought in terms of sex-stratified outcomes.

A Practical Framework for Deciding Between the Two

Use this structure to guide the conversation with your clinician, not to self-prescribe.

| Scenario | Preferred approach | |---|---| | Newly diagnosed hypothyroidism, any age | Levothyroxine monotherapy first | | Persistent symptoms (fatigue, brain fog, depression) despite TSH in range on T4 | Consider trial of low-dose T3 added to T4 | | Pregnancy or trying to conceive | Levothyroxine only | | Cardiac arrhythmia history | Use T3 with extreme caution or avoid | | DIO2 Thr92Ala variant confirmed | May be a candidate for combination therapy; discuss with endocrinologist | | Thyroid cancer follow-up (TSH suppression needed) | Levothyroxine monotherapy, at suppressive doses per oncology plan |

How Dosing Differs, and Why Women's Bodies Change the Equation

Levothyroxine Dosing Across the Female Life Span

The standard weight-based starting dose is approximately 1.6 mcg/kg/day for full replacement. In women over 60, or those with known or suspected coronary artery disease, clinicians typically start at 25-50 mcg/day and titrate slowly to avoid cardiac stress.

Dose requirements change significantly with hormonal shifts:

• Reproductive years on oral contraceptives: oral estrogen raises TBG, increasing T4 requirements by 20-50% in some women.
• Pregnancy: TSH targets are lower than non-pregnant ranges (first trimester target is typically TSH <2.5 mIU/L per ACOG and ATA joint guidance). Many pregnant women need a 25-50% dose increase, often detectable as early as the fourth to sixth week of gestation.
• Perimenopause and postmenopause: declining estrogen lowers TBG, which can mean your levothyroxine dose is suddenly too high, causing over-replacement symptoms like palpitations, anxiety, or bone loss. Annual TSH monitoring is critical at this transition.

Liothyronine Dosing

Liothyronine is typically dosed at 5-25 mcg/day when used as an add-on to levothyroxine. When used as monotherapy (which is off-label and rarely done), doses of 25-75 mcg/day in two or three divided doses are reported in the literature, but this approach is not endorsed by major guidelines because of the cardiovascular risk associated with T3 peaks.

Women with a history of atrial fibrillation, any supraventricular arrhythmia, or osteopenia should have an especially careful risk-benefit discussion before starting T3, since supraphysiologic T3 accelerates bone turnover and can trigger arrhythmias. Subclinical hyperthyroidism from over-treatment is associated with a 2-3x increased risk of atrial fibrillation and reduced bone mineral density in postmenopausal women.

Hypothyroidism Across the Female Life Stages

Reproductive Years and PCOS

Hypothyroidism is two to three times more common in women with polycystic ovary syndrome (PCOS) than in the general female population. Thyroid dysfunction worsens insulin resistance and can amplify androgen excess. Subclinical hypothyroidism in PCOS may worsen menstrual irregularity and ovulatory dysfunction. Levothyroxine is the treatment of choice. There is no evidence that adding T3 improves PCOS-specific outcomes, though this has not been formally studied.

Trying to Conceive

If you are trying to conceive, your TSH target should be below 2.5 mIU/L before you start attempting pregnancy. ASRM and ATA guidance recommends checking TSH at the first confirmation of pregnancy and adjusting the levothyroxine dose promptly. Liothyronine is not appropriate for women who are pregnant or trying to conceive (see the Pregnancy and Lactation section below).

Perimenopause

Perimenopause is when thyroid symptoms and menopausal symptoms overlap significantly. Fatigue, brain fog, mood changes, and weight gain are common to both. Many women in their 40s receive a thyroid diagnosis around the same time as perimenopausal symptoms begin, making attribution difficult. A TSH test is the first step. If you are on levothyroxine and your TSH has drifted low during perimenopause (because falling estrogen lowers TBG and raises free T4), your dose may need reduction before assuming symptoms are thyroid-related.

Postmenopause

Postmenopausal women on levothyroxine are at particular risk of over-replacement. Loss of estrogen means TBG drops, free T4 rises, and the same dose that was appropriate during your 40s may now suppress your TSH below range. Over-replacement in postmenopausal women is a meaningful clinical risk because it accelerates bone loss at a time when bone mineral density is already declining.

Pregnancy, Lactation, and Contraception Safety

Levothyroxine in Pregnancy

Levothyroxine is the only thyroid hormone replacement recommended during pregnancy. It crosses the placenta minimally in the first trimester and is considered safe at doses targeting a euthyroid state. Untreated or under-treated hypothyroidism in pregnancy is associated with preeclampsia, preterm birth, placental abruption, and impaired fetal neurodevelopment, so adequate treatment is not optional.

The American College of Obstetricians and Gynecologists (ACOG) recommends that women with known hypothyroidism have TSH checked at the first prenatal visit. Dose increases of 25-30% are often needed by weeks 4-6. Some clinicians advise women who know they are trying to conceive to take two extra levothyroxine doses per week (i.e., nine doses per week total) as a practical bridge until the first prenatal TSH is drawn.

Liothyronine in Pregnancy

Liothyronine should not be used during pregnancy. T3 crosses the placenta less efficiently than T4, and the fetal brain depends on maternal T4 for conversion to T3 within fetal tissues. Using T3 in place of or in addition to T4 during pregnancy may reduce the supply of T4 available for placental transfer, potentially impairing fetal thyroid-dependent neurodevelopment. Current guidance does not support liothyronine use in pregnant women.

If you are on a T4/T3 combination and planning pregnancy, discuss transitioning to levothyroxine monotherapy before conception.

Lactation

Levothyroxine transfers into breast milk in small amounts, but because it is a hormone naturally present in milk, it is considered compatible with breastfeeding. LactMed (NIH) classifies levothyroxine as generally safe during lactation. Liothyronine also transfers into breast milk; given the lack of safety data and the availability of the safer alternative, it should be avoided during breastfeeding unless under specialist supervision.

Contraception Considerations

Neither levothyroxine nor liothyronine is a teratogen in the classic sense, but under-treated hypothyroidism during pregnancy carries serious fetal risk. If you are sexually active and on liothyronine with no plan for pregnancy, use reliable contraception and establish a plan to switch to levothyroxine monotherapy before any planned conception.

Oral contraceptives containing estrogen raise TBG and may increase your levothyroxine dose requirement. Check TSH 6-8 weeks after starting or stopping hormonal contraception.

Who Is a Good Candidate for T3 Addition, and Who Is Not?

Women Who May Benefit from Adding Liothyronine

• Persistent fatigue, depression, or cognitive symptoms despite TSH in the normal range on adequate levothyroxine for at least 6 months
• Free T3 in the lower quartile of the reference range while on T4 therapy
• History of total thyroidectomy (the thyroid gland's own T3 production is completely absent, so reliance on peripheral conversion is total)
• Possible DIO2 polymorphism (Thr92Ala), if your clinician tests for this
• Strong patient preference after informed discussion of the limited evidence base

Women Who Should Avoid Liothyronine

• Pregnancy or trying to conceive
• Breastfeeding
• History of atrial fibrillation or other supraventricular arrhythmias
• Osteopenia or osteoporosis without concurrent bone-protective therapy
• Postmenopausal women without close cardiac and bone monitoring
• Poorly controlled anxiety or panic disorder (T3 peaks can worsen both)

Side Effects and Monitoring: What to Watch in Women

Both medications can cause symptoms of hyperthyroidism if dosed too high. The symptoms are more likely to appear, and appear faster, with liothyronine because of its rapid peak.

Shared side effects of over-treatment:

• Palpitations and tachycardia
• Insomnia
• Heat intolerance and sweating
• Anxiety and irritability
• Unintentional weight loss
• Diarrhea

Liothyronine-specific concerns:

• Symptomatic spikes 1-2 hours after dosing (sometimes called "T3 surges")
• Greater cardiovascular stress over time
• More difficult to fine-tune because of short half-life

Monitoring schedule for women:

• Newly started or dose-changed: TSH (and free T4) at 6-8 weeks
• Stable on levothyroxine: TSH annually, or sooner with life-stage changes (new OCP, pregnancy, perimenopause transition)
• On combination T4/T3: TSH plus free T3, with attention to keeping free T3 within the upper half of the reference range, not above it
• Postmenopausal on any thyroid therapy: consider baseline and periodic bone density (DEXA) if TSH has been suppressed or low-normal

Subclinical hyperthyroidism, even without frank TSH suppression to zero, is associated with increased fracture risk in women over 65. This is a reason to treat the target TSH conservatively in older women rather than aiming for the lowest possible normal value.

Female-Specific Conditions That Interact With Thyroid Therapy

Hashimoto's Thyroiditis

Hashimoto's is the most common cause of hypothyroidism in women in iodine-sufficient countries, driven by autoimmune destruction of thyroid tissue. The relationship between Hashimoto's and cycling hormones is real but under-studied. Some women describe symptom cycles that loosely follow their menstrual cycle. Levothyroxine treats the resulting hormone deficiency but does not modify the autoimmune process. There is no evidence that switching to or adding T3 changes autoantibody levels or disease progression.

Postpartum Thyroiditis

Postpartum thyroiditis affects 5-10% of women in the first year after delivery and is often missed because its symptoms (fatigue, depression, weight changes) overlap with normal postpartum experience. It typically presents as a hyperthyroid phase followed by a hypothyroid phase. Levothyroxine is appropriate in the hypothyroid phase; T3 is not indicated. Most women recover full thyroid function within 12-18 months, but up to 25% develop permanent hypothyroidism.

Female Pattern Hair Loss and Hormonal Acne

Thyroid dysfunction, particularly hypothyroidism, can cause diffuse hair shedding (telogen effluvium) and worsen acne by disrupting the hormonal environment. Neither levothyroxine nor liothyronine is a direct treatment for hair loss or acne, but restoring euthyroid status is a prerequisite before attributing these symptoms to other causes.

Perimenopause and Menopause Symptom Overlap

As noted above, the symptom overlap between hypothyroidism and perimenopause is substantial. The practical point is that treating one condition does not guarantee relief of the other. A woman whose TSH is normal on levothyroxine but who still has brain fog, weight gain, and mood changes may be experiencing perimenopause, not thyroid under-treatment, and the answer is not necessarily adding T3.

The Evidence Gap: What We Do Not Yet Know for Women

Most combination T4/T3 trials enrolled under 100 patients, ran for 3-6 months, and either did not report outcomes by sex or enrolled predominantly women without using that as an analytical variable. The Bunevicius 1999 NEJM study had 33 participants. Even the Cochrane review that synthesized 11 trials is working with a thin evidence base.

We do not have good data on:

• Whether women with Hashimoto's specifically benefit differently from combination therapy than women with post-surgical hypothyroidism
• How the DIO2 Thr92Ala polymorphism interacts with hormonal status across the menstrual cycle
• Optimal T3 dosing for postmenopausal women without creating excess bone loss risk
• Long-term cardiovascular outcomes of combination therapy in women over 60

When a clinician tells you "the evidence does not support T3 addition," they are being accurate about the trial data. When you feel that T4 monotherapy has not fully resolved your symptoms, you are also reflecting a real clinical reality that current trials have not adequately characterized.